Oncology & Hematology
Studying novel and differentiated combinations to potentially treat solid tumor cancers and blood disorders
Our mission to transform cancer care
Despite decades of progress, cancer still remains one of the world’s most serious health problems. With nearly half of our pipeline dedicated to oncology and spanning more than 30 types of cancer, our research efforts are a testament to our relentless commitment to transforming cancer care for those who need it most. The unique flexibility of our internally developed pipeline drives the potential for novel and differentiated combination therapies.
We’re building on our legacy of innovation with a deep understanding of cancer biology and the immune system. When it comes to targeting diseases like cancer, we’re demanding more for patients.
We utilize cutting-edge technologies to develop our investigational therapies, which are being evaluated both as monotherapies and in flexible combinations with the goal of providing potentially transformative treatments for cancer patients in need.
Our research includes explorations in established and emerging therapeutic modalities:
- Monoclonal antibodies and combination therapies with oncolytic viruses, vaccines and gene therapies, and other novel modalities.
- Bispecific antibodies designed to bind to two different targets, opening up a diverse array of possibilities for targeting cancer cells. We are advancing multiple candidates created with our Veloci-Bi® platform, which are designed to closely resemble natural human antibodies.
- Tumor-specific bispecifics that bind to multiple targets on the cancer cell surface
- Costimulatory bispecifics are designed to boost T-cell activation against cancer
- Small interfering RNA (siRNA) to switch off expression of genes that could trigger disease inside cells in a process called RNA interference
- CRISPR-based gene editing to deliver molecular machinery to specific cells for gene modification
We are conducting research across a broad spectrum of cancers, including solid tumor and blood cancers.
- In oncology, we are researching the role of checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies in various malignancies including lung cancer and skin cancers, lymphomas and multiple myeloma.
- In hematology, we are conducting research across a broad spectrum of blood disorders and diseases with high unmet need. Our areas of research include complement-mediated diseases, like paroxysmal nocturnal hemoglobinuria (PNH); clotting and thromboembolic disorders, including hemophilia A and B and thrombosis, TTR-amyloidosis, anemias, iron overload disorders, transplant and many other blood conditions.
Our scientific leaders discuss our advancements in cancer research
Select a Video
Behind the Science: The Next Revolution in Blood Cancer Research
Our commitment to helping patients is at the forefront of all we do. Hear from Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology, on how we’re utilizing our deep scientific knowledge and proprietary technologies to research innovative approaches to blood cancer.
Behind the Science: Defining Moments
The cancer research landscape has made great strides over the last several years. Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology, shares his perspective on pivotal moments in research advancements in the field of oncology from his career.
Behind the Science: Loving What You Do
We push the boundaries of science to help patients. Hear from Karen Rodriguez Lorenc, MD, Vice President, Global Program Head, Hematology and Translational Sciences, on why many former physician-scientists like herself are now on the frontlines of research.
Behind the Science: Paving the Way for Oncology Research
Cancer research has come a long way since Regeneron first opened its doors 35 years ago. It’s exciting to be one of the companies at the forefront of cancer research. Hear Matthew Fury, Executive Medical Director, Oncology Clinical Development, on how we are researching ways to unlock the power of the immune system for potential new solutions for patients and families in need.
Behind the Science: Power of Science
For Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology, the immuno-oncology revolution is just getting started, despite advancements over the past several years. Watch to learn more about his thoughts on the impact science has on advancing cancer research.
Video Title
Video Description